TribeMD US

Global medical education & clinical insights.
Evidence-based content for healthcare professionals.

[TribeMD US @TribeMDUS]

Understanding ATTR-CM starts with understanding its pathophysiology.

Explore expert insights from Dr. Scott Solomon and Dra. Marianna Fontana deepen your knowledge of the mechanisms behind the disease.

Complete a short knowledge check to access the video.

🎦Watch now: https://t.co/iKCJPLut8v

[TribeMD US @TribeMDUS]

The post-KRAS G12C landscape is rapidly evolving.

New agents like elisrasib and zoldonrasib, along with pan-RAS strategies, show that resistance is no longer the end, but the start of a new therapeutic line.

🔗 Read the full analysis on our website - https://t.co/02YrNBYkVj

[TribeMD US @TribeMDUS]

Personalized mRNA vaccines are gaining real momentum in oncology.

With a 49% reduction in recurrence risk in melanoma and expansion into challenging tumors like PDAC and NSCLC, AACR 2026 highlights a major step forward for this approach.

🔗 Read the full analysis on our website - https://t.co/WEeD3nsqA6

[TribeMD US @TribeMDUS]

AI is reshaping oncology and computational pathology is at the center of this transformation.

From foundation models predicting biomarkers directly from H&E to digital twins and spatial AI, AACR 2026 signals a shift from innovation to real clinical application.

🔗 Read the full analysis at the link - https://t.co/IgiEKMbjBg

[TribeMD US @TribeMDUS]

ctDNA is redefining the adjuvant treatment landscape in solid tumors.

With up to a 10-month lead time over clinical relapse, MRD detection creates a real window to act earlier — before disease becomes clinically evident.

🔗 Read the full analysis at the link - https://t.co/rLHcNjMN8E

[TribeMD US @TribeMDUS]

Cell therapy in solid tumors is entering a new phase.

From KIR-CAR tackling T cell exhaustion to smart armoring and in vivo CAR-T, #AACR2026 marks the shift from experimental to clinically actionable innovation.

Focus now: optimization, combinations, real-world impact.

🔗 https://t.co/QP7T9tsGND

[TribeMD US @TribeMDUS]

Bispecifics enter a new phase: optimization & synergy.

AACR 2026 highlights updated teclistamab data, new targets (GPRC5D, FcRH5) and ADC + BiTE combos.

Focus shifts to sequencing, rational combos & toxicity management.

🔗 https://t.co/X7q6WrLASY

[TribeMD US @TribeMDUS]

ADCs enter the precision 2.0 era.

ORR >60% in hard-to-treat cancers + multi-payload strategies mark a shift from proof of concept to optimization.

Focus now: overcoming resistance & refining sequencing, incl. ADC + IO combos.

🔗 https://t.co/CjzvTptGfL

[TribeMD US @TribeMDUS]

Updated TROPION-Breast01 data position Dato-DXd as a key post-CDK4/6i option in HR+/HER2- metastatic breast cancer.

Improved PFS, manageable toxicity, and roles in HER2-low & combos impact sequencing decisions.

TROP2 & PIK3CA may refine patient selection.

🔗 https://t.co/1PsoVzeyGt

[TribeMD US @TribeMDUS]

New SGO consensus clarifies prevention & management of endometrial cancer in Lynch Syndrome.

From universal screening to risk-reducing surgery, key evidence guides clinical decisions & personalized care.

Also covers surveillance, hormonal therapy & reproductive planning.

🔗 Read more: https://t.co/RlOJ9W3KkB

[TribeMD US @TribeMDUS]

A major shift in cervical cancer screening 🚨

HPV self-collection is now a preferred option — improving access & boosting participation, especially in underserved groups.

Earlier detection. Higher coverage. Real progress.

🔗 https://t.co/6e4VlZfFPG

[TribeMD US @TribeMDUS]

Obesity, insulin resistance & endometrial cancer are closely linked — and GLP-1 agonists may impact prevention, treatment & survivorship.

Early data point to a new oncology–endocrinology frontier.A paradigm shift in the making.

🔗 https://t.co/wocNIf5t5S

[TribeMD US @TribeMDUS]

New data at SGO 2026 🚨

Luveltamab tazevibulin (STRO-002) shows efficacy in platinum-resistant ovarian cancer with FRα ≥25%, including low–moderate expression.

Up to 80–90% of patients could benefit.

A key advance in precision oncology.

🔗 https://t.co/DXzY2Jvf8C

[TribeMD US @TribeMDUS]

DURBAC (SGO 2026): BVAC-C + durvalumab improves response in recurrent HPV+ cervical cancer.

A novel strategy combining therapeutic vaccination + immunotherapy.

What’s next for clinical practice?

🔗 https://t.co/R3qTEePqHg

[TribeMD US @TribeMDUS]

RUBY 4-year data (SGO 2026): dostarlimab shows OS benefit even in pMMR/MSS patients — supporting its use in 1L regardless of MMR status.

NRG GY-035 marks the next step: smarter combos for high-risk groups like TP53-mutated disease.

https://t.co/vzRpNUNMew

[TribeMD US @TribeMDUS]

BLUESTAR (SGO 2026) highlights AZD8205’s potential in advanced endometrial cancer — even post-immunotherapy.

With consistent responses and a high-prevalence target (B7-H4), new paths are emerging beyond checkpoint inhibitors.

What’s next for clinical practice?

🔗 https://t.co/VSPtDZaGMS

[TribeMD US @TribeMDUS]

IMGN853-0420 expands mirvetuximab’s role in ovarian cancer.

Strong responses in platinum-sensitive disease move this anti-FRα ADC earlier in the treatment continuum.

Key insights & clinical impact 👇
🔗 https://t.co/qLO4L8Oo2D

[TribeMD US @TribeMDUS]

GOG-3039 may reshape endometrioid carcinoma treatment.

Promising PFS—especially in chemo-naïve patients—supports abemaciclib + letrozole as a chemo-free, oral strategy.

Key data & clinical impact 👇
🔗 https://t.co/u0sIF8PsdI

[TribeMD US @TribeMDUS]

KEYNOTE-B96 is a game changer in ovarian cancer.

First immunotherapy regimen to show OS benefit in platinum-resistant disease — redefining this setting.

Explore the data and clinical impact 👇
🔗 https://t.co/JvVftJTHPI

[TribeMD US @TribeMDUS]

New insights in complex coronary bifurcation PCI 🚨

The DKCRUSH VIII trial showed that IVUS-guided PCI significantly reduced target vessel failure compared with angiography alone — reinforcing the role of intravascular imaging in optimizing outcomes.

🔎 Want to dive deeper into the data and clinical implications?
Check out the full analysis at the link - https://t.co/FhCbuA3qFh